04, 2026 (GLOBE NEWSWIRE) -- Noom, the leading behavior change company, today shared new real-world findings from tens of thousands of members, showing a clear relationship: members who engage more with Noom's leading GLP-1 Companion app tend to lose more weight and stay on a medication program longer
ABSTRACT As the rates of obesity and type 2 diabetes (T2D) continue to increase globally, so does the prevalence of metabolic dysfunctionassociated steatotic liver disease (MASLD)
What are the common Wegovy side effects
However, it is crucial to understand that no GLP-1 patches are currently licensed by the MHRA in the UK
Knowing what not to combine with GLP-1 therapy is essential for safe, effective treatment
These systems don't operate in isolation